Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder.

Section of Biochemical Psychiatry, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
Biological Psychiatry (Impact Factor: 9.25). 04/1997; 41(6):649-56. DOI: 10.1016/S0006-3223(96)00113-8
Source: PubMed

ABSTRACT As disturbances in guanine nucleotide binding (G) protein-coupled phosphoinositide second messenger systems have been implicated in bipolar disorder, we examined whether the abundance of G alpha q/11 and phospholipase C (PLC)-beta 1 two key transducing proteins in this signaling pathway, are altered in this disorder. Compared with the controls, immunoreactive levels of G alpha q/11 were significantly elevated by 62% (p = .047) in occipital cortex of bipolar subjects. A similar increase (52%) in the PLC-beta 1 immunolabeling was also found in the occipital cortex of the bipolar subjects, but only reached marginal statistical significance (p = .07). In contrast, frontal and temporal cortex G alpha q/11 or PLC-beta 1 immunolabeling did not differ between bipolar and control subjects. Cerebral cortical immunoreactive levels of G beta 1 or G beta 2, included as a negative control, were not different between comparison groups. These findings support and extend earlier observations suggesting that disturbances in G protein-coupled second messenger signaling pathways may play an important role in the pathophysiology of bipolar affective disorder.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mood disorders, such as bipolar and major depressive disorders, are frequent, severe, and often disabling neuropsychiatric diseases affecting millions of individuals worldwide. Available mood stabilizers and antidepressants remain unsatisfactory because of their delayed and partial therapeutic efficacy. Therefore, the development of targeted therapies, working more rapidly and being fully effective, is urgently needed. In this context, the protein kinase C (PKC) signaling system, which regulates multiple neuronal processes implicated in mood regulation, can constitute a novel therapeutic target. This paper reviews the currently available knowledge regarding the role of the PKC signaling pathway in the pathophysiology of mood disorders and the therapeutic potential of PKC modulators. Current antidepressants and mood stabilizers have been shown to modulate the PKC pathway, and the inhibition of this intracellular signaling cascade results in antimanic-like properties in animal models. Disrupted PKC activity has been found both in postmortem brains and platelet from patients with mood disorders. Finally, the PKC inhibitor tamoxifen has recently demonstrated potent antimanic properties in several clinical trials. Overall, emerging data from preclinical and clinical research suggest an imbalance of the PKC signaling system in mood disorders. Thus, PKC may be a critical molecular target for the development of innovative therapeutics.
    Molecular Neurobiology 12/2011; 44(3):407-19. · 5.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Behavioural and imaging studies report that individuals with bipolar disorder (BD) exhibit impairments in emotional face processing. However, few studies have studied the temporal characteristics of these impairments, and event-related potential (ERP) studies that investigate emotion perception in BD are rare. The aim of our study was to explore these processes as indexed by the face-specific P100 and N170 ERP components in a BD cohort. Eighteen subjects diagnosed with BD and 18 age- and sex-matched healthy volunteers completed an emotional go/no-go inhibition task during electroencephalogram (EEG) and ERP acquisition. Patients demonstrated faster responses to happy compared to sad faces, whereas control data revealed no emotional discrimination. Errors of omission were more frequent in the BD group in both emotion conditions, but there were no between-group differences in commission errors. Significant differences were found between groups in P100 amplitude variation across levels of affect, with the BD group exhibiting greater responses to happy compared to sad faces. Conversely, the control cohort failed to demonstrate a differentiation between emotions. A statistically significant between-group effect was also found for N170 amplitudes, indicating reduced responses in the BD group. Future studies should ideally recruit BD patients across all three mood states (manic, depressive, and euthymic) with greater scrutiny of the effects of psychotropic medication. These ERP results primarily suggest an emotion-sensitive face processing impairment in BD whereby patients are initially more attuned to positive emotions as indicated by the P100 ERP component, and this may contribute to the emergence of bipolar-like symptoms.
    Journal of affective disorders 04/2011; 133(1-2):212-20. · 3.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Overactivation of G-protein-mediated functions and altered G-protein regulation have been reported in bipolar disorder (BD) brain. Further, drugs effective in treating BD are reported to up-regulate expression of G-protein receptor kinase (GRK) 3 in rat frontal cortex. We therefore hypothesized that some G-protein subunits and GRK levels would be reduced in the brain of BD patients. We determined protein and mRNA levels of G-protein beta and gamma subunits, GRK2, and GRK3 in post-mortem frontal cortex from 10 BD patients and 10 age-matched controls by using immunoblots and real-time RT-PCR. There were statistically significant decreases in protein and mRNA levels of G-protein subunits beta and gamma and of GRK3 in BD brain but not a significant difference in the GRK2 level. Decreased expression of G-protein subunits and of GRK3 may alter neurotransmission, leading to disturbed cognition and behaviour in BD.
    The International Journal of Neuropsychopharmacology 05/2009; 12(6):851-60. · 5.64 Impact Factor